04.06.2012 - German Antisense Pharma has looked abroad for fresh inspiration in its management board. At the beginning of May, the Regensburg-based company appointed Dr Philippe Calais as its new Chief Executive Officer.
The Frenchman brings in more than twenty years of international experience in executive positions in both biotech and pharmaceutical firms. Calais successfully guided the development of several drugs through clinical development and commercialisation in his former positions at F. Hoffmann La-Roche and ICI Pharmaceuticals. At Antisense Pharma, he will be responsible for commercialisation of the biopharmaceutical company's lead drug candidate Trabedersen (AP 12009). The antisense drug, which blocks the Transforming GrowthFactor beta 2 (TGF-b2) from being expressed, is currently in Phase III development against glioma, as well as in Phase I/II development for pancreatic cancer and maglignant melanoma. Calais steps in for interim CEO Hubert Heinrichs, who had led the business on an interim basis since July of last year.http://www.european-biotechnology-news.com/people/bio-people/2012-2/philippe-calais.html